N,1-Dimethylazepan-4-amine | 919200-86-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: N,1-Dimethylazepan-4-amine
• CAS: 919200-86-5
• 化学式: C₈H₁₈N₂
• 分子量: 142.24
• InChiKey: QOIPDKIRDZCJER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-[4-(4-fluorophenylamino)pyrimidin-2-ylamino]benzenesulfonyl chloride hydrochloride 、 N,1-Dimethylazepan-4-amine 生成 4-[4-(4-fluorophenylamino)pyrimidin-2-ylamino]-N-methyl-N-(1-methylazepan-4-yl)benzenesulfon-amide
  参考文献：
  名称：

  Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors

  摘要：

  本公开涉及式(I)的化合物：其中R1-R5，A和Y如本公开所定义，以及包含所述化合物的组合物，制备所述化合物的方法和使用它们的方法。

  公开号：

  US20080269170A1

文献信息

• Autotaxin inhibitors
  申请人：Legrand Darren Mark

  公开号：US20140171403A1

  公开（公告）日：2014-06-19

  The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

  本发明涉及一种新型化合物，它们是自体磷脂酶A抑制剂，以及它们的制备方法、含有它们的药物组合物和药物，以及它们在由自体磷脂酶A介导的疾病和紊乱中的应用。
• Organic compounds
  申请人：BRUCE Ian

  公开号：US20090239847A1

  公开（公告）日：2009-09-24

  The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R 1 , R 2 , Ar′, A and Y are defined in the description, to compositions and use of the compounds in the treatment of inflammatory and allergic conditions.

  本发明涉及一种化合物，其化学式为(I)或其盐，适宜为药用可接受的盐，或其溶剂化合物，其中基团R1、R2、Ar′、A和Y在描述中有定义，以及该化合物在治疗炎症和过敏症状中的应用。
• Phenylpiperidine derivatives as melanocortin-4 receptor modulators
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP1842846A1

  公开（公告）日：2007-10-10

  The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及取代苯基哌啶衍生物作为黑色素皮质素-4受体调节剂。根据结构和立体化学，本发明的化合物要么是人类黑色素皮质素-4受体（MC-4R）的选择性激动剂，要么是选择性拮抗剂。激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。一般来说，涉及MC-4R调节的所有疾病和疾病都可以用本发明的化合物进行治疗。
• [EN] 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN<br/>[FR] DERIVES DE 2-PYRIDINE ALKYNE SERVANT AU TRAITEMENT DE LA DOULEUR
  申请人：EURO CELTIQUE SA

  公开号：WO2005007641A1

  公开（公告）日：2005-01-27

  The invention provides a compound of formula (I): (where R1, Q, A and R2 are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Pyridine-alkynyl Compound”); pharmaceutical compositions comprising an effective amount of a Pyridine-alkynyl Compound; and methods for treating or preventing a condition such as pain, urinary incontinence, an addictive disorder, Parkinson’s disease, parkinsonism, anxiety, epilepsy, a seizure, stroke, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington’s chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Pyridine-alkynyl Compound.

  本发明提供了化合物式(I)的化合物：（其中R1，Q，A和R2在此披露）或其药学上可接受的盐（“吡啶-炔基化合物”）；包括有效量的吡啶-炔基化合物的制药组合物；以及治疗或预防动物的疼痛、尿失禁、成瘾障碍、帕金森病、帕金森综合症、焦虑、癫痫、癫痫发作、中风、瘙痒症、精神病、认知障碍、记忆缺陷、脑功能受限、亨廷顿舞蹈症、肌萎缩侧索硬化症、痴呆、视网膜病、肌肉痉挛、偏头痛、呕吐、运动障碍或抑郁症的方法，包括向需要治疗的动物中投与有效量的吡啶-炔基化合物。
• Organic Compounds
  申请人：Bruce Ian

  公开号：US20120214800A1

  公开（公告）日：2012-08-23

  The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R 1 , R 2 , Ar′, A and Y are defined in the description, to compositions and use of the compounds in the treatment of inflammatory and allergic conditions.

  本发明涉及公式(I)的化合物或其盐，适当地为药学上可接受的盐或其溶剂，其中组R1，R2，Ar′，A和Y在说明中定义，以及该化合物在治疗炎症和过敏症状中的组合物和用途。